Induction of human papillomavirus type 16‐specific immunologic responses in a normal and an human papillomavirus‐infected populations
Open Access
- 10 April 2005
- journal article
- Published by Wiley in Immunology
- Vol. 115 (1) , 136-149
Abstract
Summary: Human papillomavirus (HPV) infection, especially with the oncogenic genotypes, is the most important risk factor for developing cervical cancer. We focused on generating HPV16 E7‐specific cytotoxic CD8+ T lymphocytes and evaluating HPV16 E7‐specific immune responses in HPV16‐infected and uninfected populations. Peripheral blood mononuclear cells (PBMCs) were first collected from an uninfected group with an human lymphocyte antigen (HLA) A2 haplotype (four volunteers). Mature monocyte‐derived dendritic cells (DCs) were generated from the PBMCs and pulsed with one of two HLA‐A2‐restricted E7 peptides, aa 11–20 [YMLDLQPETT] and aa 86–93 [TLGIVCPI], as antigen presenting cells. The autologous naïve or cultured PBMCs were then cultured with peptide‐pulsed DCs to detect the HPV16 E7‐specific immune responses by a variety of techniques such as enzyme‐linked immunosorbent assay (ELISA), enzyme‐linked immunospot (ELISPOT) assay and cytotoxic T lymphocyte assay. Interferon‐γ (IFN‐γ) from E7‐specific cytotoxic CD8+ T lymphocytes stimulated with the respective peptide was detected by ELISA. Using ELISPOT analysis, a marked increase in the number of IFN‐γ‐secreting CD8+ E7‐specific lymphocytes was observed following peptide stimulation. Cultured CD8+ T lymphocytes were highly cytotoxic against the CaSki cells. PBMCs were then colleted from an HPV16‐infected population of the HLA‐A2 haplotype, including four persons of HPV16 infection only, four with cervical intraepithelial neoplasia (CIN) lesions, and four cervical cancer patients. We then compared the immunologic responses to E7 between HPV16‐infected and uninfected populations by ELISA and ELISPOT assay. The E7‐specific immunologic responses of the HPV16‐infected populations were significantly higher than those of the uninfected population. In addition, persons with an HPV16 infection only or those with CIN lesions generated higher E7‐specific immunologic responses than cervical cancer patients. Our results demonstrate methods for evaluating E7‐sepcific immunologic responses and reflect the biological responses of HPV16‐infected people during different periods of cervical disease.Keywords
This publication has 44 references indexed in Scilit:
- Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7Journal of Cancer Research and Clinical Oncology, 2003
- Cervical cancer should be considered as a rare complication of oncogenic HPV infection rather than a STDInternational Journal of Gynecological Cancer, 2002
- Generation of Tumor-Specific Cytotoxic T Lymphocytes by Stimulation with HPV Type 16 E7 Peptide-Pulsed Dendritic Cells: An Approach to Immunotherapy of Cervical CancerGynecologic Oncology, 1999
- Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity.Journal of Experimental Medicine, 1996
- Immunological functions of non-professional antigen-presenting cells: new insights from studies of T-cell interactions with keratinocytesImmunology Today, 1994
- The genotypes and prognostic significance of human papillomaviruses in cervical cancerInternational Journal of Cancer, 1994
- Transcription patterns of human papillomavirus type 16 in genital intraepithelial neoplasia: evidence for promoter usage within the E7 open reading frame during epithelial differentiationJournal of General Virology, 1992
- The Dendritic Cell System and its Role in ImmunogenicityAnnual Review of Immunology, 1991
- Rapidly progressing cervical cancer in a patient with human immunodeficiency virus infectionGynecologic Oncology, 1990
- Behavior of Mild Cervical Dysplasia During Long-Term Follow-upObstetrics & Gynecology, 1986